Introducing Blue Jet Healthcare IPO, a significant financial opportunity with a book built issue worth Rs 840.27 crores. This offering comprises an exclusive offer for the sale of 2.43 crore shares.
Subscription for the Blue Jet Healthcare IPO opens on October 25, 2023, and closes on October 27, 2023. The allotment process is set to conclude on Wednesday, November 1, 2023. Blue Jet Healthcare IPO is slated to be listed on both BSE and NSE, with a tentative listing date fixed for Monday, November 6, 2023.
Investors can participate within a price band of ₹329 to ₹346 per share. The minimum application lot size is 43 shares, requiring a minimum investment of ₹14,878 for retail investors. Substantial Net Individual Investors (sNII) can invest in 14 lots (602 shares) with a total investment of ₹208,292, whereas big Net Individual Investors (bNII) have the option to invest in 68 lots (2,924 shares), totaling ₹1,011,704.
Blue Jet Healthcare IPO is under the expert guidance of book running lead managers including Kotak Mahindra Capital Company Limited, ICICI Securities Limited, and J.P. Morgan India Private Limited. Additionally, Link Intime India Private Ltd is the appointed registrar for this issue.
For in-depth insights, kindly refer to Blue Jet Healthcare IPO RHP for comprehensive information on this exciting opportunity.
Blue Jet Healthcare IPO Details
|IPO Date||October 25, 2023 to October 27, 2023|
|Face Value||₹2 per share|
|Price Band||₹329 to ₹346 per share|
|Lot Size||43 Shares|
|Total Issue Size||24,285,160 shares|
(aggregating up to ₹840.27 Cr)
|Offer for Sale||24,285,160 shares of ₹2|
(aggregating up to ₹840.27 Cr)
|Issue Type||Book Built Issue IPO|
|Listing At||BSE, NSE|
|Share holding pre issue||173,465,425|
|Share holding post issue||173,465,425|
|QIB Shares Offered||Not more than 50% of the Net Issue|
|Retail Shares Offered||Not less than 35% of the Net Issue|
|NII (HNI) Shares Offered||Not less than 15% of the Net Issue|
Blue Jet Healthcare IPO Dates
The IPO subscription window is set to open on October 25, 2023, and it will conclude on October 27, 2023. The crucial process of finalizing the Basis of Allotment for the Blue Jet Healthcare IPO is scheduled for Wednesday, November 1, 2023. Following this, the allotted shares will be seamlessly credited to your demat account by Friday, November 3, 2023.
|IPO Open Date||Wednesday, October 25, 2023|
|IPO Close Date||Friday, October 27, 2023|
|Basis of Allotment||Wednesday, November 1, 2023|
|Initiation of Refunds||Wednesday, November 1, 2023|
|Credit of Shares to Demat||Friday, November 3, 2023|
|Listing Date||Monday, November 6, 2023|
Blue Jet Healthcare IPO Lot Size
Explore Investment Opportunities: Interested investors have the flexibility to bid for a minimum of 43 shares and increase their investment in multiples of this figure. The table below outlines the minimum and maximum investment options available for both retail investors and High Net Worth Individuals (HNI), including the corresponding number of shares and investment amounts.
Objects of the Blue Jet Healthcare IPO
The company will not receive any proceeds from the Offer and all the Offer Proceeds will be received by the Selling Shareholders, in proportion to the Offered Shares sold by the respective Selling Shareholders as part of the Offer.
About Blue Jet Healthcare Limited IPO
Established in 1968, Blue Jet Healthcare stands as a pioneering pharmaceutical and healthcare ingredient company. Renowned for being the first manufacturer of saccharin and its salts (artificial sweeteners) in India, the company has expanded its expertise to encompass contrast media intermediates crucial for advanced medical imaging like CT scans and MRIs. Operating within three primary product categories—contrast media intermediates, high-intensity sweeteners, pharma intermediates, and active pharmaceutical ingredients—Blue Jet Healthcare has carved a niche in the global pharmaceutical landscape.
As a science-driven global entity, Blue Jet Healthcare is committed to providing:
- Process Development and Production Capabilities: With cutting-edge technology, the company excels in developing and producing pharmaceutical compounds through advanced processes.
- Global Regulatory Support: Blue Jet Healthcare offers comprehensive regulatory support on a global scale, ensuring compliance and seamless operations.
- Collaboration, Development, and Manufacturing: The company specializes in collaborative efforts, facilitating the development and manufacturing of advanced pharmaceutical intermediates and Active Pharmaceutical Ingredients (API).
Blue Jet Healthcare operates from three state-of-the-art manufacturing facilities located in Shahad (Unit I), Ambernath (Unit II), and [Location of Unit III].
With decades of expertise, Blue Jet Healthcare continues to lead the way in pharmaceutical innovation and production. Explore our range of high-quality products designed to meet the evolving needs of the healthcare industry.